骨髓增生异常综合征的诊断与分类
骨髓增生异常综合征(MDS)是无效造血导致外周血细胞减少的肿瘤性髓系增殖,需整合临床特征、骨髓与外周血形态学、免疫表型和遗传学检测作出诊断。2022年发布的国际共识分类和世界卫生组织分类(第五版)纳入形态学特征并识别3个遗传学定义的实体:孤立del(5q)细胞遗传学异常、SF3B1突变和TP53突变。
要点
- MDS诊断需整合临床特征、骨髓与外周血形态学、免疫表型和遗传学检测。
- MDS与急性髓系白血病以20%原始细胞阈值区分。
- 当前分类识别3个遗传学定义实体:孤立del(5q)、SF3B1突变和TP53突变。
核心结论
- MDS是无效造血导致外周血细胞减少的肿瘤性髓系增殖。
- MDS通过形态学发育异常与克隆性非肿瘤性髓系增殖区分,通过20%原始细胞阈值与急性髓系白血病区分。
- MDS诊断具有挑战性,需整合临床特征与骨髓及外周血形态学、免疫表型和遗传学检测。
- MDS分类旨在识别具有共同遗传学基础与分子发病机制的实体,特定亚型可结合预后风险分层指导临床决策。
研究设计与样本
- 综述,总结MDS诊断与分类,涉及2022年发布的国际共识分类和世界卫生组织分类(第五版)。
主要发现
- 当前MDS分类方案纳入形态学特征:骨髓与外周血原始细胞百分比、发育异常程度、环形铁粒幼红细胞、骨髓纤维化和骨髓低细胞性。
- 当前分类还识别3个遗传学定义的实体:孤立del(5q)细胞遗传学异常、SF3B1突变和TP53突变。
- 随着对MDS发病机制遗传学基础认识的深入,未来MDS分类预计将越来越多地基于遗传学类别。
- MDS中的形态学特征反映 underlying 异常遗传通路表型表达,无疑将继续对预后判断和治疗指导保持重要性。
关键数值与推荐
- MDS与急性髓系白血病以20%原始细胞阈值区分。
- 当前MDS分类纳入的形态学特征包括骨髓与外周血原始细胞百分比、发育异常程度、环形铁粒幼红细胞、骨髓纤维化和骨髓低细胞性。
- 当前分类识别的3个遗传学定义实体为孤立del(5q)细胞遗传学异常、SF3B1突变和TP53突变。
- 2022年发布的分类方案为国际共识分类和世界卫生组织分类(第五版)。
临床怎么用
- MDS诊断需整合临床特征与骨髓及外周血形态学、免疫表型和遗传学检测。
- MDS特定亚型可结合预后风险分层指导临床决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from nonneoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia by a blast threshold of 20%. The diagnosis of MDS can be challenging because of the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone marrow and peripheral blood morphology, immunophenotyping, and genetic testing. MDS has historically been subdivided into several subtypes by classification schemes, the most recent of which are the International Consensus Classification and World Health Organization Classification (fifth edition), both published in 2022. The aim of MDS classification is to identify entities with shared genetic underpinnings and molecular pathogenesis, and the specific subtype can inform clinical decision-making alongside prognostic risk categorization. The current MDS classification schemes incorporate morphologic features (bone marrow and blood blast percentage, degree of dysplasia, ring sideroblasts, bone marrow fibrosis, and bone marrow hypocellularity) and also recognize 3 entities defined by genetics: isolated del(5q) cytogenetic abnormality, SF3B1 mutation, and TP53 mutation. It is anticipated that with advancing understanding of the genetic basis of MDS pathogenesis, future MDS classification will be based increasingly on genetic classes. Nevertheless, morphologic features in MDS reflect the phenotypic expression of the underlying abnormal genetic pathways and will undoubtedly retain importance to inform prognosis and guide treatment.
引用
- Hasserjian RP, Germing U, Malcovati L, et al. Diagnosis and classification of myelodysplastic syndromes. Blood. 2023. PMID: 37774372. doi:10.1182/blood.2023020078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。